Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ACP-204

Small molecule · developed by ACADIA Pharmaceuticals

Phase 3 Most advanced trial

ACAD Developer

1 Registered trials

What is ACP-204?

ACP-204 is an investigational small-molecule drug studied in Lewy Body Dementia Psychosis.

At a glance

Drug type: Small molecule
Therapy area: Neurology, Psychiatry
Developer: ACADIA Pharmaceuticals Inc. (ACAD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07095465	Phase 3	Lewy Body Dementia Psychosis	Recruiting	ACAD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lewy Body Dementia Psychosis

More from ACADIA Pharmaceuticals

Pimavanserin FDA approved ACP-044 Phase 2 ACP-104 Phase 2 ACP-211 Phase 2 Carbetocin Phase 3

Sources

ClinicalTrials.gov NCT07095465

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACAD page.

Follow ACAD, the company behind ACP-204

See ACAD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACAD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z